Last updated: October 25, 2026
Tirbanibulin, marketed in the United States as Klisyri, is a prescription topical treatment for actinic keratosis on the face or scalp. Its commercial proposition is a five-day treatment course with limited dosing burden, but its price, narrow indication, recurrence profile, and competition from low-cost generic therapies constrain market expansion. Almirall’s financial disclosures show rapid growth from a small launch base, with Klisyri positioned as a dermatology growth product rather than a major group revenue driver.
What is tirbanibulin and how does Klisyri work?
Tirbanibulin 1% ointment is approved for the topical treatment of actinic keratosis in adults. The labeled regimen is once daily for five consecutive days, with one packet applied to the affected area of the face or scalp [1].
Tirbanibulin has a differentiated mechanism. It inhibits tubulin polymerization and disrupts Src kinase signaling, producing apoptosis in abnormal keratinocytes. The short treatment duration is commercially important because competing field therapies often require longer courses or generate more sustained local inflammation.
| Attribute |
Tirbanibulin, Klisyri |
| Active ingredient |
Tirbanibulin |
| Strength |
1% ointment |
| Dosage form |
Single-use topical ointment packets |
| FDA indication |
Actinic keratosis of the face or scalp |
| Treatment duration |
Once daily for five days |
| Original U.S. sponsor |
Almirall |
| FDA approval |
December 14, 2020 |
| Therapeutic category |
Prescription dermatology, precancerous skin lesions |
| Primary commercial market |
United States and selected international markets |
The label limits treatment to a contiguous area of up to 25 cm². The restricted treatment area limits use in patients with extensive field disease and can support the use of other therapies for broader lesions [1].
How large is the market for tirbanibulin?
The addressable market is the large and recurring actinic keratosis population, but the revenue opportunity is narrower than the epidemiology suggests. Actinic keratosis is common in older, fair-skinned populations and is associated with cumulative ultraviolet exposure. Many patients have multiple lesions and require repeat treatment or surveillance.
Tirbanibulin competes with:
- Generic fluorouracil cream or solution
- Imiquimod
- Diclofenac sodium gel
- Photodynamic therapy
- Cryotherapy
- Curettage and other lesion-directed procedures
- Newer topical or device-based approaches
The commercial market is segmented by treatment convenience, lesion burden, tolerability, physician preference, insurance coverage, and patient willingness to pay. Tirbanibulin is strongest where physicians value a short regimen and a comparatively manageable inflammatory reaction. It is weaker where payers prioritize generic cost or where patients need treatment across large areas.
How does tirbanibulin compare with competing actinic keratosis treatments?
| Product or modality |
Typical treatment burden |
Commercial advantage |
Commercial limitation |
| Tirbanibulin |
Five days |
Short course; topical; differentiated tolerability profile |
High branded cost; limited treatment area |
| Fluorouracil |
Often several weeks |
Low cost; established efficacy |
Prolonged inflammation and adherence burden |
| Imiquimod |
Multiple weeks, intermittent regimens |
Established immune-mediated treatment |
Longer course and local reactions |
| Diclofenac |
Often 60-90 days |
Generally tolerable |
Very long treatment period |
| Photodynamic therapy |
Office-based sessions |
Useful for field cancerization |
Procedure cost, equipment, access |
| Cryotherapy |
Single lesions or limited areas |
Immediate office treatment |
Poor fit for broad field disease; recurrence and cosmetic considerations |
The key demand driver is treatment convenience. The key market constraint is that actinic keratosis is frequently managed with inexpensive generics or procedures that physicians and payers already understand.
What has been tirbanibulin’s financial trajectory?
Almirall has identified Klisyri as one of its dermatology growth products. The product launched in the United States after FDA approval and expanded through commercialization in additional markets. Its sales trajectory has benefited from physician adoption of the five-day regimen and increased awareness of short-course topical treatment.
Public company reporting indicates a pattern of strong percentage growth from a small base:
| Period |
Financial position |
| 2020 |
FDA approval; no established commercial revenue base |
| 2021 |
Initial U.S. launch and market access buildout |
| 2022 |
Rapid growth as prescribing expanded |
| 2023 |
Continued growth, supported by broader dermatology commercialization |
| 2024 onward |
Growth opportunity remains, but comparisons become harder as the launch base increases |
Almirall reports product and business performance in euros, while Klisyri’s principal commercial exposure has been the U.S. market. Reported figures can therefore be affected by exchange rates, channel inventory, gross-to-net deductions, payer restrictions, and geographic mix [2-5].
The economic profile is attractive because topical products generally avoid the manufacturing complexity associated with injectables or biologics. The principal expenses are commercial infrastructure, physician promotion, payer access, regulatory maintenance, and manufacturing of the ointment and single-use packaging.
What revenue drivers affect Klisyri?
The main revenue drivers are:
- Prescription growth. Adoption depends on dermatologist and primary-care prescribing.
- Reimbursement. Coverage and patient copay determine whether prescriptions are filled.
- Course completion. A five-day regimen may improve adherence compared with longer topical regimens.
- Repeat treatment. Actinic keratosis is chronic and recurrent, creating potential for future courses.
- Geographic expansion. International launches can extend the product’s commercial life.
- Promotion of tolerability. Lower treatment burden can support switching from fluorouracil or imiquimod.
- Specialty pharmacy and distribution execution. Access barriers can suppress demand despite prescription growth.
The principal financial risk is that a branded product can gain prescriptions without achieving proportionate net sales if payer discounts and patient assistance increase.
When does tirbanibulin lose exclusivity?
Tirbanibulin’s exclusivity has several separate components:
- FDA regulatory exclusivity
- Orange Book-listed patent protection
- Formulation and composition patents
- Potential method-of-use patents
- Manufacturing and know-how protection
- International patent rights
FDA approval in December 2020 triggered the standard new chemical entity exclusivity period for an eligible new active ingredient. Five-year NCE exclusivity generally prevents submission of an ANDA containing a Paragraph IV certification during the initial exclusivity period, subject to the statutory framework and any applicable patent issues [6].
That regulatory exclusivity does not establish the final generic launch date. A generic applicant may challenge patents before patent expiry, and the applicant’s litigation position, settlement terms, court outcome, and patent certifications can change the effective entry date.
The most commercially relevant protection is the live Orange Book patent set. FDA’s Drugs@FDA materials and the Orange Book should be reviewed together because regulatory exclusivity and patent protection do not necessarily end at the same time [6,7].
What patents protect Klisyri and tirbanibulin?
Tirbanibulin protection is expected to center on patents covering the active compound, pharmaceutical compositions, topical formulations, dosing, and methods for treating actinic keratosis. The strength of the estate depends on claim scope and remaining patent term rather than the number of issued patents.
Key diligence questions include:
| Patent issue |
Business relevance |
| Active-ingredient claims |
Can a generic challenge the molecule directly? |
| Ointment-composition claims |
Can a generic use a materially different vehicle? |
| Particle-size or formulation claims |
Can formulation differences avoid infringement? |
| Five-day dosing claims |
Can a generic obtain approval with a different regimen or labeling strategy? |
| Actinic keratosis method claims |
Can a generic carve out the protected use? |
| Manufacturing claims |
Do production methods create a practical barrier? |
| Orange Book listing status |
Can the patent support statutory notification and litigation? |
| Patent-term adjustment or extension |
Does the effective expiry extend beyond the nominal term? |
For a topical generic, formulation patents can be more important than compound patents. The applicant may need to demonstrate pharmaceutical equivalence, comparable delivery, and acceptable product performance while avoiding infringement of valid formulation claims.
Patent strength is therefore mixed:
- Molecule-level protection: potentially meaningful, but dependent on remaining term and claim validity.
- Formulation protection: potentially stronger if the product’s vehicle, concentration, or delivery characteristics are difficult to replicate.
- Method-of-use protection: vulnerable if the generic can use a skinny label or omit a protected indication.
- Manufacturing protection: relevant only if the patented process is commercially necessary or difficult to design around.
- Regulatory exclusivity: time-limited and less durable than patent protection.
What is the Orange Book status of tirbanibulin?
Klisyri’s Orange Book status is central to generic-entry analysis. Listed patents can trigger a Paragraph IV dispute if an ANDA applicant asserts that the patents are invalid, unenforceable, or not infringed. A Paragraph IV certification can lead to litigation and, if litigation is filed within the statutory period, a 30-month stay of ANDA approval under the Hatch-Waxman framework [7,8].
The commercial consequences depend on:
- The number of listed patents
- The latest expiry date
- Whether the patents cover the approved product or only a particular use
- Whether the FDA accepts the listing
- Whether a generic can use a section viii statement or skinny label
- Whether the reference product sponsor sues
- Whether the parties settle before trial
A patent-by-patent review should distinguish nominal expiration from enforceable protection. Patent-term adjustment, terminal disclaimers, pediatric extensions, and litigation outcomes can change the effective exclusivity date.
Which companies are challenging tirbanibulin?
The generic threat is likely to come from companies with dermatology or topical semisolid capabilities, including large generic manufacturers and specialty topical manufacturers. Publicly visible competitive risk should be assessed through FDA ANDA activity, Paragraph IV notices, district-court dockets, and Orange Book updates.
No reliable conclusion about a specific challenger should be drawn from a patent listing alone. A listed patent shows potential protection; it does not establish that a company has filed an ANDA or issued a Paragraph IV notice.
What generic launch scenarios exist?
| Scenario |
Likely commercial effect |
| No ANDA challenge before key patent expiry |
Branded revenue continues until the first approved generic |
| Paragraph IV filing with settlement |
Entry date depends on the negotiated terms |
| Successful patent challenge |
Earlier generic entry and rapid price erosion |
| Skinny-label approval |
Generic may enter for non-protected uses, limiting but not eliminating branded exposure |
| Multiple generic approvals |
Faster price erosion and lower refill retention |
| Formulation-related litigation |
Potential delay if the generic depends on a protected vehicle or delivery profile |
Topical generic erosion can be slower than oral solid-dose erosion when manufacturing is difficult, but it can also be severe if several manufacturers enter simultaneously and payer formularies move quickly.
What patent litigation affects tirbanibulin?
The primary litigation risk is Hatch-Waxman litigation involving Orange Book-listed patents. The economic value of a case depends on whether the disputed claims cover the product itself or only a narrow method of use.
A strong litigation position would require:
- Claims that read directly on the commercial ointment
- A patent with substantial remaining term
- Limited design-around options
- Clear infringement evidence
- A defensible validity position
- A generic applicant that needs the disputed formulation or indication
A weaker position exists where the patent estate relies mainly on narrow dosing claims, where a generic can use a noninfringing vehicle, or where a skinny label can omit the protected method.
Settlement agreements can preserve branded revenue while giving a generic an agreed launch date. Their value depends on whether the settlement permits authorized generic competition, licenses the generic before expiry, or includes supply and distribution terms.
How does tirbanibulin compare with biologic and generic exclusivity risks?
Tirbanibulin has no biosimilar risk because it is a small-molecule topical drug, not a biologic. Its primary threat is generic substitution under the Hatch-Waxman pathway.
That risk profile differs from biologic products, where market entry depends on biosimilar approval, interchangeability, patent litigation under the Biologics Price Competition and Innovation Act, and payer substitution rules. Tirbanibulin’s risk is more directly linked to ANDA filings, formulation equivalence, Orange Book patents, and pharmacy benefit management.
What is the regulatory status of tirbanibulin?
The FDA approved Klisyri on December 14, 2020, for topical treatment of actinic keratosis on the face or scalp in adults [1]. The product is regulated as a prescription drug and is listed in FDA product information and Orange Book materials.
Regulatory opportunities include:
- Expansion into additional body sites
- Additional actinic keratosis populations
- Repeat-treatment claims
- Combination regimens
- New strengths or delivery formats
Regulatory expansion also creates patent and labeling issues. A new indication can support method-of-use protection, but the commercial value depends on whether the indication materially expands the treated population.
What licensing deals support tirbanibulin commercialization?
Almirall obtained rights to tirbanibulin through a licensing arrangement with Athenex, the company associated with the compound’s development before commercialization by Almirall. The deal gave Almirall rights to develop and commercialize the product in specified territories and supported its dermatology portfolio strategy [9].
The economics of the agreement affect the product’s net contribution. Royalty obligations, milestones, territory rights, manufacturing responsibilities, and co-promotion arrangements reduce the portion of sales retained by the commercializing company.
How strong is the tirbanibulin commercial position?
Tirbanibulin has a credible commercial position based on four factors:
- A short, simple five-day regimen
- A large actinic keratosis patient population
- A differentiated tolerability profile
- Almirall’s established dermatology infrastructure
The principal weaknesses are equally clear:
- High exposure to generic and procedural alternatives
- A limited face-and-scalp treatment area
- Dependence on reimbursement
- Recurrence and repeat-treatment uncertainty
- Lack of biosimilar-style barriers
- Potentially finite patent protection
- Limited contribution to total company revenue compared with larger dermatology products
Key Takeaways
- Tirbanibulin is a short-course topical treatment for actinic keratosis marketed as Klisyri.
- Its main commercial advantage is five-day dosing, not a broad treatment-area label.
- Almirall has reported strong growth from a small launch base, but Klisyri remains a smaller contributor to group revenue.
- The market is highly competitive with generic fluorouracil, imiquimod, diclofenac, cryotherapy, and photodynamic therapy.
- Generic risk is governed by Orange Book patents, Paragraph IV activity, formulation equivalence, and possible skinny-label strategies.
- Tirbanibulin faces generic rather than biosimilar competition.
- Formulation and method-of-use patents may be more commercially important than molecule-level protection.
- The most important valuation variables are net sales growth, payer access, repeat treatment, patent expiry, and the timing of the first generic entrant.
FAQs
Is tirbanibulin a generic or branded drug?
Tirbanibulin is marketed as the branded prescription product Klisyri. Generic tirbanibulin entry would require FDA approval of an ANDA or another applicable regulatory pathway.
Can tirbanibulin be used on the arms, legs, or hands?
The FDA-approved label covers actinic keratosis on the face or scalp. Use on other body sites is outside the approved indication unless separately authorized.
Does tirbanibulin have biosimilar competition?
No. Tirbanibulin is a small-molecule topical drug, so its relevant competitive pathway is generic substitution rather than biosimilar approval.
Why might a generic tirbanibulin launch be delayed?
A launch can be delayed by Orange Book patent litigation, the 30-month stay, formulation development, manufacturing validation, regulatory review, settlement terms, or a court ruling upholding relevant patents.
What is the largest long-term risk to Klisyri revenue?
The largest long-term risk is generic or therapeutic substitution after regulatory and patent exclusivity decline. Generic pricing, payer coverage, and physician willingness to use inexpensive alternatives could produce rapid net-sales erosion.
References
- U.S. Food and Drug Administration. (2020). Klisyri (tirbanibulin) ointment, 1% prescribing information.
- Almirall, S.A. (2021). Annual report 2021.
- Almirall, S.A. (2022). Annual report 2022.
- Almirall, S.A. (2023). Annual report 2023.
- Almirall, S.A. (2024). Annual report 2024.
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
- U.S. Code. (2024). 21 U.S.C. § 355: New drugs.
- Athenex, Inc. (2017). Corporate disclosures regarding the tirbanibulin licensing agreement with Almirall.
